Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Operating Income (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Operating Income for 7 consecutive years, with -$7.5 million as the latest value for Q4 2024.

  • On a quarterly basis, Operating Income rose 27.44% to -$7.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$42.1 million, a 18.87% increase, with the full-year FY2024 number at -$42.1 million, up 18.87% from a year prior.
  • Operating Income was -$7.5 million for Q4 2024 at Actinium Pharmaceuticals, up from -$12.6 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$5.1 million in Q2 2021 to a low of -$24.9 million in Q4 2021.
  • A 4-year average of -$10.6 million and a median of -$10.1 million in 2022 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: skyrocketed 54.74% in 2022, then tumbled 124.32% in 2023.
  • Actinium Pharmaceuticals' Operating Income stood at -$24.9 million in 2021, then surged by 54.74% to -$11.3 million in 2022, then rose by 8.4% to -$10.3 million in 2023, then increased by 27.44% to -$7.5 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Operating Income are -$7.5 million (Q4 2024), -$12.6 million (Q3 2024), and -$12.4 million (Q2 2024).